Journal article

Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations

DM Hyman, B Tran, L Paz-Ares, JP MacHiels, JH Schellens, PL Bedard, M Campone, PA Cassier, J Sarantopoulos, U Vaishampayan, R Chugh, A Mahipal, AC Lockhart, C Sessa, T Zander, M Ng, G Curigliano, J Bendiske, X Chen, S Choudhury Show all

JCO Precision Oncology | Published : 2019


PURPOSE Concurrent PIK3CA mutations and fibroblast growth factor receptor (FGFR) alterations occur in multiple cancer types, including estrogen receptor–positive breast cancer, bladder cancer, and endometrial cancer. In this first-in-human combination trial, we explored safety and preliminary efficacy of combining the PI3Kα selective inhibitor alpelisib with the FGFR1-4 selective inhibitor infigratinib. PATIENTS AND METHODS Patients with PIK3CA-mutant advanced solid tumors, with or without FGFR1-3 alterations, were enrolled in the dose escalation or one of three molecular-defined dose-expansion cohorts. The primary end point was the maximum tolerated dose. Secondary end points included safet..

View full abstract

Citation metrics